|
![]() |
|
|
Lidocaine
drug data and news
Lidocaine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Lidocaine | ||
| Brand Names/Synonyms | Lignocaine; Cappicaine; Maricaine; Leostesin; Gravocain; Esracaine; Anestacon; Duncaine; Isicaina; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Alphacaine; Anestacon Jelly; Dalcaine; DermaFlex; Dilocaine; Emla; L-Caine; Lanabiotic; Lidocaine; Lidoderm; Lidoject-1; Lidoject-2; Norwood Sunburn Spray; Octocaine; Octocaine-100; Octocaine-50; Rocephin Kit; Xylocaine; Xylocaine 5% Spinal; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; Xylocaine-MPF; Xylocaine-MPF with Glucose; Xylocard; Zilactin-L | ||
| Indication | For use as Dermal anesthesia | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Lidocaine is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidocaine appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidocaine in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide. | ||
| Mechanism Of Action | Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. | ||
| Lidocaine News (When available) |
Adolor Corporation to Present at the Lehman Brothers' Ninth Annual ... 07 Mar 2006 Adolor Corporation to Present at the Lehman Brothers' Ninth Annual ... 07 Mar 2006 The Analgesic Effect of Nitroglycerin Added to Lidocaine on ... Feb 21, 2006 Sontra eases the pain of needles Mar 3, 2006 Is TNS Really No Big Deal? Feb 14, 2006 Yengo daughter tells Mar 4, 2006 Adolor Corporation Reports Year End 2005 Financial Results Mar 2, 2006 Does Dexamethasone Improve the Quality of Intravenous Regional ... Feb 6, 2006 Longtime judge dies at 76 Mar 3, 2006 Sontra Medical Introduces Generation 1.75 SonoPrep(R) Skin ... Feb 7, 2006 Positive late stage data for Corgentech's painkiller Feb 22, 2006 Corgentech kids' pain drug shows promise Feb 21, 2006 Blurred Vision as the only Symptom of a Positive Epidural Test ... Feb 21, 2006 Needle-wary dental patients now have option Feb 21, 2006 Continuous Epidural Block Versus Continuous Popliteal Nerve Block ... Feb 21, 2006 Famous last words: 'This won't hurt a bit' Feb 22, 2006 Nerve Blocks of the Lower Limb Feb 22, 2006 Columbia Laboratories to Discuss Fourth Quarter and Year End 2005 ... Feb 24, 2006 Fast-Acting Local Anesthetic Reduces Pain from Needles Feb 22, 2006 Sontra Medical Introduces Generation 1.75 SonoPrep(R) Skin ... Feb 7, 2006 Carl Hiaasen I’m not making this up … well, maybe I am Jan 31, 2006 Sontra Medical Introduces Generation 1.75 SonoPrep(R) Skin ... Feb 7, 2006 FDA Warns About Risks of Throat-Numbing Spray Feb 14, 2006 Mr. President, we need a national healthcare system Feb 13, 2006 Chemical Eye on Genes Made for America Feb 18, 2006 New mouthwash helps with pain linked to head and neck cancer Feb 3, 2006 Gut Reaction Feb 8, 2006 Endo reports strong quarter, year results Feb 16, 2006 Adolor "buy," target price raised Feb 9, 2006 Journal of the American Podiatric Medical Association Feb 9, 2006 Pain relief: Finding the right drug Feb 9, 2006 New dental pain reliever Feb 13, 2006 Hawkins deputy seizes drugs, handgun in traffic stop Feb 14, 2006 Anika gets EU OK to sell wrinkle filler Feb 17, 2006 Study: Supplements can relieve arthritis pain Feb 16, 2006 Pain In Horses Feb 4, 2006 Risk of Serious Harm and/or Death With Potential IV/SC ... Feb 15, 2006 Routine Inhaled Induction in Adults: A Safe Practice? Feb 14, 2006 Anika Therapeutics Receives CE Mark for its REDEFYNE(TM) Cosmetic ... Feb 16, 2006 Entereg’s Positive Phase III Data Drive Up Adolor’s Stock Feb 8, 2006 New mouthwash might help alleviate pain Feb 1, 2006 Vyteris plans to lay off third of staff, citing high inventory Feb 1, 2006 Sontra Medical Serves Patent Infringement Notice for Dermisonics' ... Feb 1, 2006 Altea Therapeutics and Teikoku Seiyaku Co. Ltd. Enter into an ... Feb 1, 2006 | ||
| Dosage Forms | CREAM; GEL; IMPLANT; JELLY; KIT; LIQUID; OINTMENT; SOLUTION; SPRAY | ||
| Drug_Category | Antiarrhythmic Agents; Anesthetics; Antiarrhythmic Agents; ATC:C01BB01; ATC:C05AD01; ATC:D04AB01; ATC:N01BB02; ATC:R02AD02; ATC:S01HA07; ATC:S02DA01 | ||
| Absorption | Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. | ||
| Interactions | Interactions for Lidocaine: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential. Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-diethylamino-N-(2,6-dimethylphenyl)-ethanamide | ||
| Chemical Formula | C14H22N2O | ||
| Molecular Weight | 234.337 g/mol | ||
| Smiles String | CCN(CC)CC(=O)NC1=C(C=CC=C1C)C | ||
| Melting Point | Not Available | ||
| Water Solubility | 4100 mg/L | ||
| State | Liquid | ||
| LogP/Hphobicity | 2.478 | ||
| Isoelectric Point | 8.01 | ||
| Biotransformation | Primarily hepatic | ||
| Half Life | 109 minutes | ||
| Protein Binding [%] | 60-80% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Lidocaine.html http://www.rxlist.com/cgi/generic2/xylocaineinj.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00479 | ||
| CAS Registry Number | 137-58-6 | ||
| KEGG Compound ID | C07073 | ||
| PubChem ID | SID:151886 | ||
| PharmGKB ID | PA450226 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 712884 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |